The bioavailability of flufenamic acid and its dissolution rate from capsules.
The bioavailabilities of five commercially available flufenamic acid (FA) capsules were studied in humans and beagle dogs. The dissolution rates of these capsules were determined by several methods. Experiments on in vitro/in vivo and humans/dogs correlations were performed to evaluate the dissolution test methods and the values of beagle dogs as models for predicting bioavailability of weak acid drugs in humans. Significant differences in the rates and extents of bioavailability of the different capsules were observed both in humans and dogs, but results in humans differed from those in dogs. The dissolution rates, determined by dissolution methods involving pretreatment with acidic solutions, correlated significantly with bioavailabilities in humans and dogs; however, those obtained by the rotating basket and paddle methods without any surface active agents did not correlate with in vivo data.
D000328:Adult; D000818:Animals; D001682:Biological Availability; D002214:Capsules; D004285:Dogs; D005260:Female; D005439:Flufenamic Acid / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D012995:Solubility; D013045:Species Specificity; D013050:Spectrometry, Fluorescence
D002214:Capsules; D005439:Flufenamic Acid